Lung Cancer: Overview

摘要: Lung cancer is the leading cause of cancer-related death in world and 90% all cases are caused by tobacco smoking. divided into two major histologic subtypes, non-small cell (NSCLC) small (SCLC), with distinct biological behavior, genetic alterations, therapy. Thus far, screening for lung has not been proven effective since no modality shown to decrease mortality. Most patients both SCLC NSCLC present symptoms either locally advanced or metastatic disease, only about 25% having early-stage, resectable disease. For stage I II NSCLC, surgical resection treatment choice results long-term survival 60–80% 40–50% patients, respectively. III, limited-stage SCLC, aggressive chemotherapy plus radiotherapy can offer a cure 20–25% patients. Stage IV, metastatic, extensive-stage incurable diseases which prolong palliate symptoms. Recent advances our understanding molecular biology have led novel therapeutic strategies targeting relevant pathways that regulate proliferation and/or progression cancer. Several these molecularly targeted therapies now demonstrated significant clinical benefits subsets